Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, Iglesias-Rodriguez M, St John G, Nivens MC, Kanamaluru V, Fairhurst J, Ishii T, Maldonado R, Choy E, Emery P. Xu C, et al. Among authors: ishii t. J Clin Pharmacol. 2021 May;61(5):714-724. doi: 10.1002/jcph.1795. Epub 2021 Jan 26. J Clin Pharmacol. 2021. PMID: 33314148 Free article.
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators. Ogata A, et al. Among authors: ishii t. J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834203 Clinical Trial.
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT. Paccaly AJ, et al. Among authors: ishii t. J Clin Pharmacol. 2021 Jan;61(1):90-104. doi: 10.1002/jcph.1703. Epub 2020 Jul 29. J Clin Pharmacol. 2021. PMID: 32726514 Free PMC article. Clinical Trial.
Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Sugisaki K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group. Hirabayashi Y, et al. Among authors: ishii t. Mod Rheumatol. 2016 Nov;26(6):828-835. doi: 10.3109/14397595.2016.1160991. Epub 2016 Apr 21. Mod Rheumatol. 2016. PMID: 26934116
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S; SHINOBI study group. Ogata A, et al. Among authors: ishii t. Mod Rheumatol. 2018 Jan;28(1):76-84. doi: 10.1080/14397595.2017.1332507. Epub 2017 Jun 16. Mod Rheumatol. 2018. PMID: 28622048 Clinical Trial.
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R; SHINOBI Study Group. Ogata A, et al. Among authors: ishii t. Mod Rheumatol. 2019 Sep;29(5):767-774. doi: 10.1080/14397595.2018.1533514. Epub 2018 Dec 14. Mod Rheumatol. 2019. PMID: 30299202 Clinical Trial.
4,359 results